Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women

Women's Health

Volumn 9, Issue 6, 2013, Pages 557-567

  Magge, Suma S ^a   Wolf, Jacqueline L ^b  

^a NORWALK HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

acupuncture; Chinese herbs; complementary and alternative medicine; irritable bowel syndrome; Padma Lax; peppermint oil; probiotics; psychological therapy; STW 5; Tong Xie Yao Fang

Indexed keywords

BITTER CANDYTUFT MONOEXTRACT; CHINESE DRUG; DIGESTIVE TRACT AGENT; GASTROINTESTINAL AGENT; MIYARISAN; PADMA; PADMA LAX; PEPPERMINT OIL; PLACEBO; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROBIOTIC AGENT; STW 5; STW 5 II; TONG XIE YAO FANG; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUPUNCTURE; ALTERNATIVE MEDICINE; ANUS DISEASE; BRADYCARDIA; CHINESE HERB; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONSTIPATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLATULENCE; GUT DIRECTED HYPNOTHERAPY; HEADACHE; HEARTBURN; HERBAL MEDICINE; HUMAN; IRRITABLE COLON; LOOSE FECES; MUSCLE DISEASE; MUSCLE TREMOR; OUTCOME ASSESSMENT; PERIANAL BURNING; PSYCHOTHERAPY; QUALITY OF LIFE; RASH; REVIEW; THERAPY EFFECT;

ACUPUNCTURE THERAPY; COGNITIVE THERAPY; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MIND-BODY THERAPIES; PLANT PREPARATIONS; PROBIOTICS; RELAXATION THERAPY; TREATMENT OUTCOME;

EID: 84887222601     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.13.57     Document Type: Review

References (85)

1. Everhart J. Functional intestinal disorders. In: The Burden of Digestive Diseases in the United States. US Department of Health and Human Services. Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Offce, Washington, DC, USA, 111-114 (2008).
2. Tillisch K. Complementary and alternative medicine for functional gastrointestinal disorders. Gut 55(5), 593-596 (2006).
3. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62 (1), 159-176 (2013).
4. Ringel Y, Maharshak N. The intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. doi:10.1152/ajpgi.00207.2012 (2013) (Epub ahead of print).
5. Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 302(10), G1075-G1084 (2012).
6. Agrawal A, Whorwell P. BMJ learning: irritable bowel syndrome: diagnosis and management. BMJ 332(7536), 280-283 (2006). (Pubitemid 43235341)
7. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130 (5), 1480-1491 (2006).
8. Brandt LJ, Chey WD, Foxx-Orenstein AE et al.; American College of Gastroenterolgy Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 104(Suppl. 1), S1-S35 (2009).
9. Hasler WL. Traditional thoughts on the pathophysiology of irritable bowel syndrome. Gastroenterol. Clin. North Am. 40 (1), 21-43 (2011).
10. Gwee KA. Irritable bowel syndrome in developing countries-a disorder of civilization or colonization? Neurogastroenterol. Motil. 17(3), 317-324 (2005).
11. Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol. Clin. North Am. 40(1), 1-10 (2011).
12. Chang L, Toner BB, Fukudo S et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 130(5), 1435-1446 (2006).
13. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Effcacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 104(7), 1831-1843 (2009).
14. Yoon S, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome in adults: conventional and complementary/alternative approaches. Altern. Med. Rev. 16(2), 134-151 (2011).
15. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Effcacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 58(3), 367-378 (2009).
16. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris J W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 10(8), C D 003460 (2011).
17. Koloski N, Talley N, Huskic S, Boyce P. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. Aliment. Pharmaco. Ther. 17(6), 841-851 (2003). (Pubitemid 36418882)
18. Kong SC, Hurlstone DP, Pocock CY et al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J. Clin. Gastroenterol. 39(2), 138-141 (2005). (Pubitemid 40130027)
19. van Tilburg MA, Palsson OS, Levy RL et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement. Altern. Med. 8(1), 46 (2008).
20. Magge S, Lembo A. Low-FODMAP diet for treatment of irritable bowel syndrome. Gastroenterol. Hepatol. 8(11), 739-745 (2012).
21. Morelli L. FAO/WHO guidelines on probiotics: 10 years later. J. Clin. Gastroenterol. 46(9), S1-S2 (2012).
22. Quigley E. Therapies aimed at the gut microbiota and infammation: antibiotics, prebiotics, probiotics, synbiotics, anti-infammatory therapies. Gastroenterol. Clin. North Am. 40(1), 207-222 (2011).
23. Sanders ME, Guarner F, Guerrant R et al. An update on the use and investigation of probiotics in health and disease. Gut 62(5), 787-796 (2013).
24. Metchnikoff E, Metchnikoff II, Mitchell PC. The Prolongation of Life: Optimistic Studies. Springer Publishing Company, NY, USA (2004).
25. Tissier H. Traitement des infections intestinales par la méthode de la fore bactérienne de l'intestin. CR Soc. Biol. 60, 359-361 (1906).
26. Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial fora. Science 308(5728), 1635-1638 (2005). (Pubitemid 40807514)
27. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol. Rev. 90(3), 859-904 (2010).
28. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect. Dis. Clin. North Am. 24(4), 943-959 (2010).
29. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136(6), 2003-2014 (2009).
30. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat. Rev. Microbiol. 10 (1), 66-78 (2012).
31. Spiller R, Card T, Mearin F et al. Incidence and characteristics of postinfectious IBS (PI-IBS): a multinational internet survey. Gut 59(Suppl. III), A32 (2010).
32. Longstreth GF, Hawkey C, Mayer E et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment. Pharmacol. Ther. 15(7), 959-964 (2001). (Pubitemid 32578967)
33. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136(6), 1979-1988 (2009).
34. Ford AC, Spiegel B, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 7(12), 1279-1286 (2009).
35. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 22(5), 512-519, e114-e115(2010).
36. Malinen E, Rinttilä T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastroenterol. 100(2), 373-382 (2005). (Pubitemid 40314522)
37. Si J, Yu Y, Fan Y, Chen S. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J. Gastroenterol. 10(12), 1802-1805 (2004). (Pubitemid 38931209)
38. Kerckhoffs AP, Samsom M, van der Rest ME et al. Lower bifdobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J. Gastroenterol. 15 (23), 2887-2892 (2009).
39. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 14(17), 2650-2661 (2008).
40. Moayyedi P, Ford AC, Talley NJ et al. The effcacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59(3), 325-332 (2010).
41. Clarke G, Cryan J, Dinan T, Quigley E. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment. Pharmacol. Ther. 35(4), 403-413 (2012).
42. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol. 104(4), 1033-1049 (2009).
43. Whorwell PJ, Altringer L, Morel J et al. Effcacy of an encapsulated probiotic Bifdobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101(7), 1581-1590 (2006). (Pubitemid 43980633)
44. Kaptchuk TJ. Acupuncture: theory, effcacy and practice. Ann. Intern. Med. 136(5), 374-383 (2002).
45. Lembo AJ, Conboy L, Kelley JM et al. A treatment trial of acupuncture in IBS patients. Am. J. Gastroenterol. 104(6), 1489-1497 (2009).
46. Manheimer E, Wieland LS, Cheng K et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 107(6), 835-847 (2012).
47. Manheimer E, Cheng K, Wieland LS et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 16(5), CD005111 (2012).
48. Moffet HH. Sham acupuncture may be as effcacious as true acupuncture: a systematic review of clinical trials. J. Altern. Complement. Med. 15(3), 213-216 (2009).
49. Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651), 999-1003 (2008). (Pubitemid 351656091)
50. Kaptchuk TJ, Stason WB, Davis RB et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ 332(7538), 391-397 (2006).
51. Liu JP, Yang M, Liu Y, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 1, CD004116 (2006).
52. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine. JAMA 280 (18), 1585-1589 (1998). (Pubitemid 28520646)
53. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment. Pharmacol. Ther. 19(3), 271-279 (2004). (Pubitemid 38253501)
54. ® Lax, a Tibetan herbal formula. Digestion 65(3), 161-171 (2002). (Pubitemid 34914035)
55. Bian Z, Wu T, Liu L et al. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J. Altern. Complement. Med. 12(4), 401-407 (2006). (Pubitemid 43807599)
56. Pan F, Zhang T, Zhang Y, Xu J, Chen F. Effect of TongXie YaoFang granule in treating diarrhea-predominate irritable bowel syndrome. Chinese J. Integrat. Med. 15 (3), 216-219 (2009).
57. von Arnim U, Peitz U, Vinson B, Gundermann K, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am. J. Gastroenterol. 102, 1268-1275 (2007). (Pubitemid 46802028)
58. Pittler M, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am. J. Gastroenterol. 93(7), 1131-1135 (1998). (Pubitemid 29080964)
59. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J. Gastroenterol. 32 (6), 765-768 (1997).
60. ®) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig. Liver Dis. 39(6), 530-536 (2007). (Pubitemid 46746646)
61. Alam MS, Roy PK, Miah AR et al. Effcacy of peppermint oil in diarrhea predominant IBS-a double blind randomized placebo-controlled study. Mymensingh Med. J. 22(1), 27-30 (2013).
62. Charrois TL, Hrudey J, Gardiner P, Vohra S. Peppermint oil. Pediatr. Rev. 27(7), 349-351 (2006).
63. Naliboff B, Munakata J, Fullerton S et al. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 41(4), 505-512 (1997).
64. Verne GN, Robinson ME, Price DD. Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain 93(1), 7-14 (2001). (Pubitemid 32530837)
65. Tillisch K, Labus JS, Naliboff BD et al. Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am. J. Gastroenterol. 100(4), 896-904 (2005). (Pubitemid 40592385)
66. Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J. Neurogastroenterol. Motil. 17(2), 131-139 (2011).
67. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J. Consul. Clin. Psychol. 72(6), 1100-1113 (2004). (Pubitemid 39658543)
68. Kearney DJ, Brown-Chang J. Complementary and alternative medicine for IBS in adults: mind-body interventions. Nat. Clin. Pract. Gastroenterol. Hepatol. 5(11), 624-636 (2008).
69. Zijdenbos IL, de Wit NJ, van der Heijden, Geert J, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst. Rev. 1, CD006442 (2009).
70. Fernandez C, Amigo I. Effcacy of training in stress and contingency management in cases of irritable bowel syndrome. Stress Health 22(5), 285-295 (2006). (Pubitemid 46062161)
71. Boyce PM, Talley NJ, Balaam B et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am. J. Gastroenterol. 98(10), 2209-2218 (2003). (Pubitemid 37305361)
72. van Der Veek PP, van Rood YR, Masclee AA. Clinical trial: short-and long-term beneft of relaxation training for irritable bowel syndrome. Aliment. Pharmacol. Ther. 26(6), 943-952 (2007). (Pubitemid 47346714)
73. Webb A, Kukuruzovic R, Catto-Smith A, Sawyer S. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. 4, CD005110 (2007).
74. Moser G, Trägner S, Gajowniczek EE et al. Long-term success of gut-directed group hypnosis for patients with refractory irritable bowel syndrome: a randomized controlled trial. Am. Gastroenterol. 108(4), 602-609 (2013).
75. Lowén MB, Mayer EA, Sjöberg M et al. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment. Pharmacol. Ther. 37(3), 1184-1197 (2013).
76. MacFarlane S, MacFarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment. Pharmacol. Ther. 24(5), 475-486 (2006).
77. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifdobacterium animalis DN-173010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment. Pharmacol. Ther. 26(3), 475-486 (2007). (Pubitemid 47063138)
78. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifdobacterium bifdum MIMBb75 signifcantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled s t udy. Aliment. Pharmacol. Ther. 33(10), 1123-1132 (2011).
79. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int. J. Colorectal Dis. 27(4), 467-474 (2012).
80. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol. 18(30), 4012-4018 (2012).
81. Choi CH, Jo SY, Park HJ, Chang SK, Byeon J, Myung S. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J. Clin. Gastroenterol. 45(8), 679-683 (2011).
82. Ringel-Kulka T, Palsson OS, Maier D et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifdobacterium lactis bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J. Clin. Gastroenterol. 45(6), 518-525 (2011).
83. Sinn DH, Song JH, Kim HJ et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig. Dis. Sci. 53(10), 2714-2718 (2008).
84. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J. Pediatr. 147(2), 197-201 (2005). (Pubitemid 41207833)
85. Kim H, Vazquez Roque M, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol. Motil. 17(5), 687-696 (2005). (Pubitemid 41400717)